Non-insulin remedies for diabetes include drugs and treatments that help control blood sugar levels without using insulin, such as GLP -1 receptor agonist, SGLT 2 inhibitors, DPP -4 inhibitors, and lifestyle or device -based intervention. The market for these remedies is increasing due to the spread of growing global diabetes, an increase in demand for easy-to-use and low aggressive remedies, innovation in oral and injectable drug formulations, and weight loss compared to insulin, heart safety and better patients such as their additional benefits.
Key Growth Drivers and Opportunities
Rising Global Prevalence of Diabetes: The increasing global proliferation of diabetes, sedentary lifestyle, unhealthy diet and aging population are promoting considerable demand for effective and convenient treatment options. As more patients are diagnosed especially with type 2 diabetes there is a growing requirement of treatments managing blood sugar without complications of insulin use. Non-insulin therapy provides benefits such as weight loss and heart safety, such as oral administration, low side effects, and additional health benefits, making them a favorite option and accelerates their market growth.
Challenges
Non-insulin therapy for diabetes market faces many challenges, including high treatment costs, limited access to low and medium-income countries, and concerns on long-term security and side effects of new drug classes. Additionally, the patient may be affected by complex doses regimens or gastrointestinal side effects, and competition from insulin-based treatments remains stronger in some segments. Regulatory barriers and extensive clinical trials also slow down the introduction of innovative remedies.
Innovation and Expansion
IDF Establishes a Working Group to Examined New Type 5 Diabetes
In April 2025, A working group to create formal diagnostic criteria and treatment guidelines for a type of diabetes associated with malnutrition that was officially designated as “type 5 diabetes” during an international meeting of experts in India earlier this year was announced by IDF President Professor Peter Schwarz at the recent International Diabetes Federation (IDF) World Diabetes Congress 2025 in Bangkok, Thailand. Additionally, the working group will create educational modules to teach healthcare professionals and a worldwide research registry.
Between 20 and 25 million individuals globally are thought to have type 5 diabetes, mostly in Asia and Africa. This discovery represents a turning point in our knowledge of diabetes and its impact on undernourished and lean adolescents and young adults in low- and middle-income (LMIC) nations.
Cipla Takes Center Stage as CDSCO Authorized the Launch of Inhaled Insulin
In December 2024, Following the Central Drugs Standard Control Organization’s (CDSCO) approval of Cipla‘s exclusive distribution and marketing of Afrezza, an inhalation human insulin, in India, the company’s stock will continue to be closely watched.
Unlike existing insulins that are administered as injections, Afrezza is a rapid-acting insulin that is administered via inhalation. When taken at the start of a meal, Afrezza dissolves swiftly in the lungs when inhaled orally and immediately gets insulin into the circulation.
Inventive Sparks, Expanding Markets
Through R&D innovation, strategic alliances, and entry into developing markets, non-insulin treatment firms are propelling growth. They concentrate on creating safer, more efficient medications, utilizing digital technologies to assist patients, and obtaining authorization for more extensive therapeutic applications. The key players operating the Non-Insulin Therapies for Diabetes Market include AstraZeneca, Bristol-Myers Squibb, BoehringerIngelheim GmbH, Eli Lilly and Company, and others.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
